ES2141182T3 - Vacuna contra la enfermedad de lyme. - Google Patents

Vacuna contra la enfermedad de lyme.

Info

Publication number
ES2141182T3
ES2141182T3 ES94112145T ES94112145T ES2141182T3 ES 2141182 T3 ES2141182 T3 ES 2141182T3 ES 94112145 T ES94112145 T ES 94112145T ES 94112145 T ES94112145 T ES 94112145T ES 2141182 T3 ES2141182 T3 ES 2141182T3
Authority
ES
Spain
Prior art keywords
burgdorferi
ecacc
antigen
accordance
vaccine against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94112145T
Other languages
English (en)
Inventor
Markus M Dr Simon
Ulrich E Schaible
Klaus Prof Dr Eichmann
Michael Dr Kramer
Wallich Dr Reinhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25885304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2141182(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deutsches Krebsforschungszentrum DKFZ, Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2141182T3 publication Critical patent/ES2141182T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A UNA VACUNA PASIVA CONTRA LA ENFERMEDAD DE LYME, QUE CONTIENE UNO O MULTIPLES ANTICUERPOS MONOCLONALES ESPECIFICOS PARA EL 31 KD ANTIGENO (OSPA) O/Y EL 34 KD ANTIGENO (OSPB) DEL B. BURGDORFERI, A PARTIR DE ANIMALES DE INVESTIGACION INMUNODEFICIENTES, QUE SON INFECTADOS CON EL ORGANISMO B. BURGDORFERI PATOGENO CON CAPACIDAD DE VIDA, PARA EVITAR LA FORMACION DE ARTRITIS, PANCARDITIS Y HEPATITIS. LA INVENCION SE REFIERE ADEMAS A UN PROCEDIMIENTO PARA LA OBTENCION DE VACUNAS DE ACUERDO CON LA INVENCION, COMO EL HIBRIDOMAZELLINIEN ECACC 89 09 1302, ECACC 90050405, ECACC 90050406 Y ECACC 90050407, QUE DE ACUERDO CON LA INVENCION SEGREGAN ANTICUERPOS Y EL TRONCO ZS7 (DSM 5527) DEL B. BURGDORFERI PATOGENO. EVENTUALMENTE EL OBJETO DE LA INVENCION ES TAMBIEN UN ANTIGENO A PARTIR DEL B. BURGDORFERI, QUE REACCIONA DE FORMA INMUNE CON UNA ANTICUERPO DE ACUERDO CON LA INVENCION, UN PROCESO PARA LA OBTENCION DE ANTIGENOS DE ACUERDO CON LA INVENCION, ASI COMO VACUNAS ACTIVAS CONTRALA ENFERMEDAD DE LYME, CONTENIENDO ANTIGENOS DE ACUERDO CON LA INVENCION COMO COMPONENTE ESENCIAL. LA INVENCION SE REFIERE FINALMENTE A UN PROCESO PARA EL AISLAMIENTO Y RECULTIVO DEL ORGANISMO B. BURGDORFERI PATOGENO A PARTIR DE ANIMALES DE INVESTIGACION INMUNODEFICIENTES.
ES94112145T 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme. Expired - Lifetime ES2141182T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3931236 1989-09-19
DE4015911A DE4015911A1 (de) 1989-09-19 1990-05-17 Impfstoff gegen die lyme-krankheit

Publications (1)

Publication Number Publication Date
ES2141182T3 true ES2141182T3 (es) 2000-03-16

Family

ID=25885304

Family Applications (4)

Application Number Title Priority Date Filing Date
ES94112143T Expired - Lifetime ES2129551T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.
ES94112145T Expired - Lifetime ES2141182T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.
ES94112144T Expired - Lifetime ES2145077T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.
ES90117943T Expired - Lifetime ES2082812T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94112143T Expired - Lifetime ES2129551T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES94112144T Expired - Lifetime ES2145077T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.
ES90117943T Expired - Lifetime ES2082812T3 (es) 1989-09-19 1990-09-18 Vacuna contra la enfermedad de lyme.

Country Status (23)

Country Link
US (6) US5178859A (es)
EP (5) EP0418827B1 (es)
JP (3) JP3205932B2 (es)
KR (2) KR100205462B1 (es)
AT (4) ATE175576T1 (es)
AU (1) AU651560B2 (es)
CA (1) CA2025597C (es)
CZ (2) CZ284538B6 (es)
DE (5) DE4015911A1 (es)
DK (4) DK0633028T3 (es)
ES (4) ES2129551T3 (es)
FI (1) FI102248B1 (es)
GR (3) GR3018995T3 (es)
HR (1) HRP940545B1 (es)
HU (2) HU212716B (es)
IE (1) IE903377A1 (es)
NO (2) NO311767B1 (es)
NZ (1) NZ235260A (es)
PL (2) PL170229B1 (es)
PT (1) PT95349B (es)
SI (1) SI9011773B (es)
SK (3) SK283089B6 (es)
YU (2) YU48250B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5582829A (en) * 1990-04-05 1996-12-10 Rx Technologies, Inc. Sonicated borrelia burgdorferi vaccine
JPH06501382A (ja) 1990-06-15 1994-02-17 エール ユニバーシティ ライム病の予防および診断に用いる組成物および方法
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
JPH07501687A (ja) * 1991-08-15 1995-02-23 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ボレリア・ブルグドルフェリのサブグループのｏｓｐ　ａ　蛋白、それをコードしている遺伝子およびワクチン
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
AU2903892A (en) * 1991-10-22 1993-05-21 Symbicom Aktiebolag Improvement in (borrelia burgdorferi) diagnosis and prophylaxis
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US5558993A (en) * 1994-06-17 1996-09-24 The Regents Of The University Of California Cloned Borrelia burgdorferi virulence protein
GB9511909D0 (en) * 1995-06-12 1995-08-09 Microbiological Res Authority Vaccine
US6437116B1 (en) 1996-02-21 2002-08-20 Board Of Regents, The University Of Texas System VMP-like sequences of pathogenic borrelia
DE19632862B4 (de) * 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6458555B1 (en) * 1996-08-21 2002-10-01 Gerd Bach Cytologic method of examining mucous membranes
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
DE19740735A1 (de) * 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
US6306623B1 (en) 1998-02-24 2001-10-23 The University Of California Leptospiral major outer membrane protein LipL32
PT1100922E (pt) 1998-07-31 2008-05-30 Gundersen Lutheran Medical Fou Utilização do(s) epítopo(s) borrelicida(s) da proteína de superfície externa c (ospc) de borrelia burgdorferi, como vacina
WO2000056298A2 (en) * 1999-03-19 2000-09-28 Luitpold Pharmaceuticals, Inc. Treatment of lyme disease with polysulfated glycosaminoglycan formulations
US6592875B1 (en) 1999-06-21 2003-07-15 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
EP2292762A3 (en) 2002-12-20 2012-12-12 Board of Regents, The University of Texas System VMP-like sequences of pathogenic Borrelia species and strains
BRPI0719360B1 (pt) 2006-11-03 2016-09-06 Intervet Int Bv vacina da doença de lyme canina, e, uso de organismos de uma genoespécie de borrelia
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
AU2010322085B2 (en) * 2009-11-17 2016-09-15 Zoetis Services Llc Peptides and methods for the detection of Lyme disease antibodies
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
US9610336B1 (en) * 2014-07-16 2017-04-04 Amiram Katz Immunotherapy for lyme disease
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4772464A (en) 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4888276A (en) * 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US5034515A (en) * 1987-09-22 1991-07-23 Wisconsin Alumni Research Foundation Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
AU7058691A (en) * 1989-12-22 1991-07-24 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologically active proteines from borrelia burgdorferi, related test kits and vaccine
JPH06501382A (ja) * 1990-06-15 1994-02-17 エール ユニバーシティ ライム病の予防および診断に用いる組成物および方法
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
JPH07501687A (ja) * 1991-08-15 1995-02-23 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ボレリア・ブルグドルフェリのサブグループのｏｓｐ　ａ　蛋白、それをコードしている遺伝子およびワクチン
JP3246603B2 (ja) * 1991-08-27 2002-01-15 ノボザイムス アクティーゼルスカブ 洗 剤
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
WO1993007897A1 (en) * 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins

Also Published As

Publication number Publication date
US5686267A (en) 1997-11-11
HU212716B (en) 1996-10-28
EP0643974B1 (de) 1999-01-13
ES2129551T3 (es) 1999-06-16
YU49370B (sh) 2005-09-19
DE59010863D1 (de) 1999-02-25
HU211228A9 (en) 1995-11-28
DK0643974T3 (da) 1999-09-06
EP0633028B1 (de) 1999-11-17
JPH03209400A (ja) 1991-09-12
FI102248B (fi) 1998-11-13
NO315905B1 (no) 2003-11-10
PT95349B (pt) 1997-06-30
KR100202128B1 (en) 1999-06-15
HU905816D0 (en) 1991-03-28
SI9011773A (sl) 1998-04-30
JP3205932B2 (ja) 2001-09-04
EP0633313B1 (de) 2000-04-05
CZ456090A3 (cs) 1998-08-12
ATE186646T1 (de) 1999-12-15
EP0643974A1 (de) 1995-03-22
NO20014624D0 (no) 2001-09-24
HK1002405A1 (en) 1998-08-21
NZ235260A (en) 1993-04-28
CZ284538B6 (cs) 1998-12-16
JP2001204467A (ja) 2001-07-31
FI904597A0 (fi) 1990-09-18
NO311767B1 (no) 2002-01-21
GR3032010T3 (en) 2000-03-31
DE59009978D1 (de) 1996-02-01
US6613331B1 (en) 2003-09-02
PL170229B1 (pl) 1996-11-29
ES2145077T3 (es) 2000-07-01
NO904062L (no) 1991-03-20
HRP940545A2 (en) 1997-04-30
HRP940545B1 (en) 2000-06-30
CZ284616B6 (cs) 1999-01-13
US5780030A (en) 1998-07-14
ATE175576T1 (de) 1999-01-15
EP0633028A1 (de) 1995-01-11
PT95349A (pt) 1991-05-22
AU6244490A (en) 1991-03-28
SK283088B6 (sk) 2003-02-04
DE4015911A1 (de) 1991-03-28
CA2025597A1 (en) 1991-03-20
JP2001069969A (ja) 2001-03-21
AU651560B2 (en) 1994-07-28
DK0633313T3 (da) 2000-07-24
CZ97095A3 (en) 1995-09-13
SK280285B6 (sk) 1999-11-08
US5856447A (en) 1999-01-05
JP3418171B2 (ja) 2003-06-16
EP0861664A2 (de) 1998-09-02
DE59010903D1 (de) 2000-05-11
US5178859A (en) 1993-01-12
FI102248B1 (fi) 1998-11-13
SI9011773B (en) 2001-12-31
EP0418827B1 (de) 1995-12-20
DK0418827T3 (da) 1996-05-06
ATE191499T1 (de) 2000-04-15
SK456090A3 (en) 1999-11-08
KR100205462B1 (ko) 1999-07-01
HK1013620A1 (en) 1999-09-03
ES2082812T3 (es) 1996-04-01
YU48250B (sh) 1997-09-30
JP3328644B2 (ja) 2002-09-30
EP0418827A1 (de) 1991-03-27
IE990173A1 (en) 2000-11-01
YU9097A (sh) 1999-06-15
SK283089B6 (sk) 2003-02-04
GR3033675T3 (en) 2000-10-31
SK151098A3 (en) 1999-04-13
DE59010888D1 (de) 1999-12-23
PL169804B1 (pl) 1996-09-30
KR910005889A (ko) 1991-04-27
YU177390A (sh) 1993-05-28
CA2025597C (en) 2004-02-03
ATE131732T1 (de) 1996-01-15
EP0633313A1 (de) 1995-01-11
EP0861664A3 (de) 1999-02-24
NO904062D0 (no) 1990-09-18
US5434077A (en) 1995-07-18
IE903377A1 (en) 1991-04-10
SK151198A3 (en) 1999-04-13
GR3018995T3 (en) 1996-05-31
HUT59613A (en) 1992-06-29
DK0633028T3 (da) 2000-04-10
NO20014624L (no) 1991-03-20

Similar Documents

Publication Publication Date Title
ES2141182T3 (es) Vacuna contra la enfermedad de lyme.
Sauerwein et al. Transmission blocking malaria vaccines: Assays and candidates in clinical development
Burgdorfer et al. Rhipicephalus sanguineus: vector of a new spotted fever group rickettsia in the United States
FI93310B (fi) Menetelmä rokotteen valmistamiseksi piluksia kantavien nisäkkään kudoksiin tarttuvien bakteerien aiheuttamia tauteja vastaan
DE69333397D1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
Esser et al. Trypanosoma rhodesiense blood forms express all antigen specificities relevant to protection against metacyclic (insect form) challenge.
ES2174839T3 (es) Oligosido derivado de un poliosido antigenico obtenido de un agente patogeno.
DE69132417D1 (de) Impfstoff gegen die Lyme-Krankheit
Man et al. Evaluation of a major surface antigen of Babesia microti merozoites as a vaccine candidate against Babesia infection
ES2114064T3 (es) Inmunoanalisis para la deteccion de colageno o fragmentos de colageno.
ES2104712T3 (es) Adyuvantes y vacunas mejorados.
FR2618680B1 (fr) Antigenes d'excretion-secretion specifiques de toxoplasma gondii, leurs produits d'expression, leur procede d'obtention et leurs applications diagnostiques et prophylactiques
DE69030099D1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
DE69031426D1 (de) Impfstoff zur immunisierung von katzen gegen toxoplasmen ohne verbreitung der oozysten
CN104059134B (zh) 败血性巴氏杆菌毒素重组蛋白及其应用
DE69333730D1 (de) Impfstoff, der acemannan als adjuvans enthält
ATE151994T1 (de) Aufspüren und behandeln von infektionen durch verwendung von immunokonjukaten
Nussenzweig et al. Antibodies against sporozoites of human and simian malaria produced in rats
ATE138269T1 (de) Zweiphasensystem zur herstellung und präsentation von fremdantigenen in hybriden lebendimpfstoffen
Esteves et al. Identification of Ehrlichia ruminantium (Gardel strain) IFN-γ inducing proteins after vaccination with a killed vaccine
SU1667870A1 (ru) Штамм хламидий СнLамYDIа рSIттасI, используемый дл изготовлени биопрепаратов дл диагностики и профилактики хламидиоза серебристо-черных лисиц
White An evaluation of immunoglobulin isotype expression in immunity to the rodent malarial parasite, Plasmodium Yoelii
Saphra et al. A New Salmonella Type: S. Virginia.
Weitz The Lister Institute of Preventive Medicine, Elstree, Hertfordshire

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 633028

Country of ref document: ES